JP7121660B2 - 癌を処置するためのｅｚｈ２阻害剤の使用 - Google Patents

癌を処置するためのｅｚｈ２阻害剤の使用 Download PDF

Info

Publication number
JP7121660B2
JP7121660B2 JP2018562564A JP2018562564A JP7121660B2 JP 7121660 B2 JP7121660 B2 JP 7121660B2 JP 2018562564 A JP2018562564 A JP 2018562564A JP 2018562564 A JP2018562564 A JP 2018562564A JP 7121660 B2 JP7121660 B2 JP 7121660B2
Authority
JP
Japan
Prior art keywords
alkyl
cancer
linker
halo
cyano
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2018562564A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019517491A5 (enExample
JP2019517491A (ja
Inventor
リビチ スコット
ソメニウス マイケル
Original Assignee
エピザイム，インコーポレイティド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by エピザイム，インコーポレイティド filed Critical エピザイム，インコーポレイティド
Publication of JP2019517491A publication Critical patent/JP2019517491A/ja
Publication of JP2019517491A5 publication Critical patent/JP2019517491A5/ja
Application granted granted Critical
Publication of JP7121660B2 publication Critical patent/JP7121660B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2018562564A 2016-06-01 2017-06-01 癌を処置するためのｅｚｈ２阻害剤の使用 Expired - Fee Related JP7121660B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662344338P 2016-06-01 2016-06-01
US62/344,338 2016-06-01
PCT/US2017/035391 WO2017210395A1 (en) 2016-06-01 2017-06-01 Use of ezh2 inhibitors for treating cancer

Publications (3)

Publication Number Publication Date
JP2019517491A JP2019517491A (ja) 2019-06-24
JP2019517491A5 JP2019517491A5 (enExample) 2020-07-09
JP7121660B2 true JP7121660B2 (ja) 2022-08-18

Family

ID=60477941

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018562564A Expired - Fee Related JP7121660B2 (ja) 2016-06-01 2017-06-01 癌を処置するためのｅｚｈ２阻害剤の使用

Country Status (6)

Country Link
US (2) US11786533B2 (enExample)
EP (1) EP3464643A4 (enExample)
JP (1) JP7121660B2 (enExample)
AU (1) AU2017273726B2 (enExample)
CA (1) CA3025933A1 (enExample)
WO (1) WO2017210395A1 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3363B1 (ar) 2011-04-13 2019-03-13 Epizyme Inc مركبات بنزين مستبدلة بأريل أو أريل غير متجانس
KR20190105669A (ko) 2012-10-15 2019-09-17 에피자임, 인코포레이티드 암을 치료하는 방법
US11786533B2 (en) 2016-06-01 2023-10-17 Epizyme, Inc. Use of EZH2 inhibitors for treating cancer
US11147819B2 (en) 2016-06-17 2021-10-19 Epizyme, Inc. EZH2 inhibitors for treating cancer
WO2018102687A2 (en) * 2016-12-02 2018-06-07 Epizyme, Inc. Combination therapy for treating cancer
US10266542B2 (en) 2017-03-15 2019-04-23 Mirati Therapeutics, Inc. EZH2 inhibitors
WO2018183885A1 (en) 2017-03-31 2018-10-04 Epizyme, Inc. Combination therapy for treating cancer
AU2018275123A1 (en) * 2017-06-02 2020-01-30 Epizyme, Inc. Use of EZH2 inhibitors for treating cancer
JP7399079B2 (ja) * 2017-09-05 2023-12-15 エピザイム，インコーポレイティド 癌を処置するための併用療法
DK3746446T3 (da) 2018-01-31 2022-06-27 Mirati Therapeutics Inc PRC2-inhibitorer
US20210260051A1 (en) * 2018-06-14 2021-08-26 Board Of Regents, The University Of Texas System Combination of ezh2 inhibitor and checkpoint therapy for the treatment of cancer
US12421228B2 (en) 2019-04-22 2025-09-23 Mirati Therapeutics, Inc. Naphthyridine derivatives as PRC2 inhibitors
CN114269748A (zh) 2019-06-05 2022-04-01 米拉蒂医疗股份有限公司 作为用于治疗癌症的PRC2抑制剂的咪唑并[1,2-c]嘧啶衍生物
WO2021063331A1 (zh) * 2019-09-30 2021-04-08 江苏恒瑞医药股份有限公司 EZH2抑制剂与含有TGF-β受体的融合蛋白联合在制备治疗肿瘤的药物中的用途
US12502434B2 (en) 2019-10-31 2025-12-23 Daegu-Gyeongbuk Medical Innovation Foundation Compound comprising EZH2 inhibitor and E3 ligase binder and pharmaceutical composition for preventing or treating EZH2-associated disease comprising same as active ingredient
CN111303133A (zh) * 2020-03-25 2020-06-19 清华大学 降解ezh2蛋白的小分子化合物
EP4267136A4 (en) * 2020-12-23 2025-02-05 Cascade Prodrug Inc. Combination therapy with a vinca alkaloid n-oxide and an immune checkpoint inhibitor
CN119136808A (zh) * 2022-12-30 2024-12-13 清华大学 药物组合物及其应用
WO2024238381A1 (en) * 2023-05-12 2024-11-21 Taipei Medical University Dual ezh2-hsp90 inhibitors

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018522045A (ja) 2015-08-03 2018-08-09 コンステレーション・ファーマシューティカルズ・インコーポレイテッドＣｏｎｓｔｅｌｌａｔｉｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． Ｅｚｈ２阻害剤および制御性ｔ細胞機能の調節

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2482903A (en) * 2010-08-19 2012-02-22 Software Imaging Technology Ltd A print engine
BR112013005806B1 (pt) 2010-09-10 2022-05-10 Epizyme, Inc Métodos para detectar se um indivíduo é um candidato para o tratamento com ou responsivo a um inibidor de ezh2 e usos terapêuticos do dito inibidor de ezh2
US9175331B2 (en) * 2010-09-10 2015-11-03 Epizyme, Inc. Inhibitors of human EZH2, and methods of use thereof
WO2012118812A2 (en) 2011-02-28 2012-09-07 Epizyme, Inc. Substituted 6,5-fused bicyclic heteroaryl compounds
TW201733984A (zh) 2011-04-13 2017-10-01 雅酶股份有限公司 經取代之苯化合物
JO3363B1 (ar) * 2011-04-13 2019-03-13 Epizyme Inc مركبات بنزين مستبدلة بأريل أو أريل غير متجانس
CA3177515A1 (en) 2012-03-12 2013-09-19 Epizyme, Inc. Inhibitors of human ezh2, and methods of use thereof
ES2617379T3 (es) 2012-04-13 2017-06-16 Epizyme, Inc. Forma de sal de un inhibidor de histona metiltransferasa EZH2 humana
EP2836216B1 (en) 2012-04-13 2022-06-08 Epizyme, Inc. Combination therapy for treating cancer
US9856320B2 (en) 2012-05-15 2018-01-02 Bristol-Myers Squibb Company Cancer immunotherapy by disrupting PD-1/PD-L1 signaling
US9445426B2 (en) * 2012-08-06 2016-09-13 Broadcom Corporation Apparatuses, methods and computer program products related to improvements in autonomous denial prohibition mechanisms
US20140062720A1 (en) * 2012-09-06 2014-03-06 John Murray Spruth Remote Pipeline Corrosion Protection and Valve Monitoring Apparatus
BR112015008480A2 (pt) 2012-10-15 2017-07-04 Epizyme Inc compostos de benzeno substituído
KR20190105669A (ko) 2012-10-15 2019-09-17 에피자임, 인코포레이티드 암을 치료하는 방법
US20150283142A1 (en) * 2013-03-15 2015-10-08 Infinity Pharmaceuticals, Inc. Treatment of cancers using pi3 kinase isoform modulators
EP2934531A4 (en) * 2012-12-19 2016-06-15 Glaxosmithkline Llc COMBINATION
CA2894216A1 (en) 2012-12-21 2014-06-26 Epizyme, Inc. 1,4-pyridone compounds
CA2894222A1 (en) 2012-12-21 2014-06-26 Epizyme, Inc. 1,4-pyridone bicyclic heteroaryl compounds
EP2970306A4 (en) 2013-03-15 2016-08-03 Epizyme Inc SUBSTITUTED 6.5-CONDENSED BICYCLIC HETEROARYL COMPOUNDS
US20160031907A1 (en) 2013-03-15 2016-02-04 Epizyme, Inc. Substituted Benzene Compounds
WO2014165422A1 (en) 2013-04-02 2014-10-09 Merck Sharp & Dohme Corp. Immunohistochemical assay for detecting expression of programmed death ligand 1 (pd-l1) in tumor tissue
EP3022184B1 (en) 2013-07-19 2017-09-27 Epizyme, Inc. Substituted benzene compounds
US9624205B2 (en) 2013-07-19 2017-04-18 Epizyme, Inc. Substituted 6,5-fused bicyclic heteroaryl compounds
PE20161273A1 (es) 2013-10-16 2016-12-18 Epizyme Inc Forma salina de hidrocloruro para la inhibicion de ezh2
WO2015058125A1 (en) 2013-10-18 2015-04-23 Epizyme, Inc. Method of treating cancer
MX373187B (es) 2013-12-06 2020-04-13 Epizyme Inc Terapia de combinación para tratar cáncer.
US20150320754A1 (en) * 2014-04-16 2015-11-12 Infinity Pharmaceuticals, Inc. Combination therapies
EA038337B1 (ru) 2014-06-17 2021-08-11 Эпизим, Инк. Ингибиторы ezh2 для лечения лимфомы
EP3160940A4 (en) 2014-06-25 2018-05-02 Epizyme, Inc. Substituted benzene and 6,5-fused bicyclic heteroaryl compounds
CN106794177A (zh) * 2014-10-16 2017-05-31 Epizyme股份有限公司 治疗癌症的方法
KR102964530B1 (ko) 2014-11-17 2026-05-13 에피자임, 인코포레이티드 암을 치료하기 위한 방법
MX375970B (es) 2014-12-23 2025-03-06 Novartis Ag Compuestos de triazolopirimidina y usos de los mismos.
MX391720B (es) 2015-04-20 2025-03-21 Epizyme Inc Terapia combinada para tratar cáncer.
EA201890009A1 (ru) 2015-06-10 2018-07-31 Эпизайм, Инк. Ингибиторы ezh2 для лечения лимфомы
WO2017035234A1 (en) 2015-08-24 2017-03-02 Epizyme, Inc. Method for treating cancer
US20180296563A1 (en) 2015-09-25 2018-10-18 Epizyme, Inc. Method of treating malignant rhabdoid tumor of the ovary (mrto)/small cell cancer of the ovary of the hypercalcemic type(sccoht) with an ezh2 inhibitor
WO2017062495A2 (en) 2015-10-06 2017-04-13 Epizyme, Inc. Method of treating medulloblastoma with an ezh2 inhibitor
WO2017079757A1 (en) 2015-11-06 2017-05-11 Epizyme, Inc. Pediatric dosing for treatment of cancer with an ezh2 inhibitor
EP3386513A2 (en) 2015-12-07 2018-10-17 Epizyme Inc Inhibitors of ezh2 and methods of use thereof
US11951108B2 (en) 2016-01-29 2024-04-09 Epizyme, Inc. Combination therapy for treating cancer
US20190038633A1 (en) 2016-02-08 2019-02-07 Epizyme, Inc. Methods of treating cancer
US11786533B2 (en) 2016-06-01 2023-10-17 Epizyme, Inc. Use of EZH2 inhibitors for treating cancer
US11147819B2 (en) 2016-06-17 2021-10-19 Epizyme, Inc. EZH2 inhibitors for treating cancer
WO2018102687A2 (en) 2016-12-02 2018-06-07 Epizyme, Inc. Combination therapy for treating cancer
CN110366413A (zh) 2017-02-02 2019-10-22 Epizyme股份有限公司 癌症治疗形式
WO2018183885A1 (en) 2017-03-31 2018-10-04 Epizyme, Inc. Combination therapy for treating cancer
AU2018275123A1 (en) 2017-06-02 2020-01-30 Epizyme, Inc. Use of EZH2 inhibitors for treating cancer

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018522045A (ja) 2015-08-03 2018-08-09 コンステレーション・ファーマシューティカルズ・インコーポレイテッドＣｏｎｓｔｅｌｌａｔｉｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． Ｅｚｈ２阻害剤および制御性ｔ細胞機能の調節

Also Published As

Publication number Publication date
EP3464643A4 (en) 2020-04-01
CA3025933A1 (en) 2017-12-07
AU2017273726B2 (en) 2023-10-19
WO2017210395A1 (en) 2017-12-07
US20220288085A1 (en) 2022-09-15
US11786533B2 (en) 2023-10-17
AU2017273726A1 (en) 2018-12-06
EP3464643A1 (en) 2019-04-10
US20240139203A1 (en) 2024-05-02
JP2019517491A (ja) 2019-06-24

Similar Documents

Publication Publication Date Title
US11786533B2 (en) Use of EZH2 inhibitors for treating cancer
JP2023071905A (ja) 癌を処置するためのｅｚｈ２阻害剤
US11951109B2 (en) EZH2 inhibitors for treating lymphoma
JP2023095928A (ja) 癌を処置するためのｅｚｈ２阻害剤の使用
US20220160721A1 (en) Methods of treating cancer
JP6779793B2 (ja) リンパ腫を治療するためのｅｚｈ２阻害剤
JP2024001203A (ja) 癌を処置するための併用療法
JP2018062535A (ja) ガンの治療方法
JP2019503391A (ja) 癌を処置するための併用療法
JP2018513865A (ja) 癌を処置するための併用療法
JP2023026523A (ja) 癌処置様式
CN108025191A (zh) 治疗癌症的方法
JP2017532338A (ja) 癌を治療する方法
WO2017097215A1 (zh) 内嵌脲类结构的wnt通路抑制剂

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200526

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200526

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210706

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20211004

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220105

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220607

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220624

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220805

R150 Certificate of patent or registration of utility model

Ref document number: 7121660

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees